Kuvan now indicated for children under four years
Kuvan (sapropterin dihydrochloride; Merck Serono) is now indicated for use in children with phenylketonuria under four years old who have shown to be responsive. The recommended method of administration in children up to 20kg has also been revised.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069053
Recommended from Pharmaceutical Press